spacer
spacer

PDBsum entry 1aaq

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Hydrolase/hydrolase inhibitor PDB id
1aaq

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
99 a.a. *
Ligands
PSI
Waters ×1
* Residue conservation analysis
PDB id:
1aaq
Name: Hydrolase/hydrolase inhibitor
Title: Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected t-cell assays
Structure: HIV-1 protease. Chain: a, b. Engineered: yes
Source: Human immunodeficiency virus 1. Organism_taxid: 11676. Expressed in: escherichia coli. Expression_system_taxid: 562
Biol. unit: Dimer (from PQS)
Resolution:
2.50Å     R-factor:   0.190    
Authors: M.Lewis
Key ref:
G.B.Dreyer et al. (1992). Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry, 31, 6646-6659. PubMed id: 1637805 DOI: 10.1021/bi00144a004
Date:
13-Apr-92     Release date:   22-Jun-94    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
P03367  (POL_HV1BR) -  Gag-Pol polyprotein from Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI)
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1447 a.a.
99 a.a.*
Key:    Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class 1: E.C.2.7.7.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 2: E.C.2.7.7.49  - RNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 3: E.C.2.7.7.7  - DNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 4: E.C.3.1.-.-
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 5: E.C.3.1.13.2  - exoribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
   Enzyme class 6: E.C.3.1.26.13  - retroviral ribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 7: E.C.3.4.23.16  - HIV-1 retropepsin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1021/bi00144a004 Biochemistry 31:6646-6659 (1992)
PubMed id: 1637805  
 
 
Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
G.B.Dreyer, D.M.Lambert, T.D.Meek, T.J.Carr, T.A.Tomaszek, A.V.Fernandez, H.Bartus, E.Cacciavillani, A.M.Hassell, M.Minnich.
 
  ABSTRACT  
 
Analogues of peptides ranging in size from three to six amino acids and containing the hydroxyethylene dipeptide isosteres Phe psi Gly, Phe psi Ala, Phe psi NorVal, Phe psi Leu, and Phe psi Phe, where psi denotes replacement of CONH by (S)-CH(OH)CH2, were synthesized and studied as HIV-1 protease inhibitors. Inhibition constants (Ki) with purified HIV-1 protease depend strongly on the isostere in the order Phe psi Gly greater than Phe psi Ala greater than Phe psi NorVal greater than Phe psi Leu greater than Phe psi Phe and decrease with increasing length of the peptide analogue, converging to a value of 0.4 nM. Ki values are progressively less dependent on inhibitor length as the size of the P1' side chain within the isostere increases. The structures of HIV-1 protease complexed with the inhibitors Ala-Ala-X-Val-Val-OMe, where X is Phe psi Gly, Phe psi Ala, Phe psi NorVal, and Phe psi Phe, have been determined by X-ray crystallography (resolution 2.3-3.2 A). The crystals exhibit symmetry consistent with space group P6(1) with strong noncrystallographic 2-fold symmetry, and the inhibitors all exhibit 2-fold disorder. The inhibitors bind in similar conformations, forming conserved hydrogen bonds with the enzyme. The Phe psi Gly inhibitor adopts an altered conformation that places its P3' valine side chain partially in the hydrophobic S1' pocket, thus suggesting an explanation for the greater dependence of the Ki value on inhibitor length in the Phe psi Gly series. From the kinetic and crystallographic data, a minimal inhibitor model for tight-binding inhibition is derived in which the enzyme subsites S2-S2' are optimally occupied. The Ki values for several compounds are compared with their potencies as inhibitors of proteolytic processing in T-cell cultures chronically infected with HIV-1 (MIC values) and as inhibitors of acute infectivity (IC50 values). There is a rank-order correspondence, but a 20-1000-fold difference, between the values of Ki and those of MIC or IC50. IC50 values can approach those of Ki but are highly dependent on the conditions of the acute infectivity assay and are influenced by physiochemical properties of the inhibitors such as solubility.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
20490879 J.P.Yesudas, F.B.Sayyed, and C.H.Suresh (2011).
Analysis of structural water and CH···π interactions in HIV-1 protease and PTP1B complexes using a hydrogen bond prediction tool, HBPredicT.
  J Mol Model, 17, 401-413.  
20662079 S.L.Chen, D.X.Zhao, and Z.Z.Yang (2011).
An estimation method of binding free energy in terms of ABEEMσπ/MM and continuum electrostatics fused into LIE method.
  J Comput Chem, 32, 338-348.  
17869270 E.C.Johnson, E.Malito, Y.Shen, B.Pentelute, D.Rich, J.Florián, W.J.Tang, and S.B.Kent (2007).
Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors.
  J Mol Biol, 373, 573-586.
PDB codes: 2j9j 2j9k
16627941 J.Dusková, J.Dohnálek, T.Skálová, H.Petroková, E.Vondrácková, M.Hradílek, J.Konvalinka, M.Soucek, J.Brynda, M.Fábry, J.Sedlácek, and J.Hasek (2006).
On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
  Acta Crystallogr D Biol Crystallogr, 62, 489-497.
PDB codes: 1zsf 1zsr
15981257 C.Bartels, A.Widmer, and C.Ehrhardt (2005).
Absolute free energies of binding of peptide analogs to the HIV-1 protease from molecular dynamics simulations.
  J Comput Chem, 26, 1294-1305.  
16163299 J.Wang (2005).
DNA polymerases: Hoogsteen base-pairing in DNA replication?
  Nature, 437, E6.
PDB code: 1zet
14993705 B.Pillai, K.K.Kannan, S.V.Bhat, and M.V.Hosur (2004).
Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction.
  Acta Crystallogr D Biol Crystallogr, 60, 594-596.  
11170058 T.Goto, T.Nakano, T.Kohno, S.Morimatsu, C.Morita, W.Hong, Y.Kiso, M.Nakai, and K.Sano (2001).
Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
  J Med Virol, 63, 203-209.  
9646869 A.Wlodawer, and J.Vondrasek (1998).
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
  Annu Rev Biophys Biomol Struct, 27, 249-284.  
  9797203 D.Boden, and M.Markowitz (1998).
Resistance to human immunodeficiency virus type 1 protease inhibitors.
  Antimicrob Agents Chemother, 42, 2775-2783.  
9485411 R.B.Rose, C.S.Craik, and R.M.Stroud (1998).
Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
  Biochemistry, 37, 2607-2621.
PDB code: 1az5
9428710 J.Konvalinka, J.Litera, J.Weber, J.Vondrásek, M.Hradílek, M.Soucek, I.Pichová, P.Majer, P.Strop, J.Sedlácek, A.M.Heuser, H.Kottler, and H.G.Kräusslich (1997).
Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase.
  Eur J Biochem, 250, 559-566.  
9061782 M.Miller, M.Geller, M.Gribskov, and S.B.Kent (1997).
Analysis of the structure of chemically synthesized HIV-1 protease complexed with a hexapeptide inhibitor. Part I: Crystallographic refinement of 2 A data.
  Proteins, 27, 184-194.  
  8798968 A.H.Kaplan (1996).
Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: a guide for drug design.
  AIDS Res Hum Retroviruses, 12, 849-853.  
  8738429 C.S.Dukes, T.J.Matthews, D.M.Lambert, G.B.Dreyer, S.R.Petteway, and J.B.Weinberg (1996).
Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates.
  AIDS Res Hum Retroviruses, 12, 777-782.  
8894111 E.E.Rutenber, F.McPhee, A.P.Kaplan, S.L.Gallion, J.C.Hogan, C.S.Craik, and R.M.Stroud (1996).
A new class of HIV-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere.
  Bioorg Med Chem, 4, 1545-1558.
PDB code: 3aid
  8528086 A.Wallqvist, R.L.Jernigan, and D.G.Covell (1995).
A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design.
  Protein Sci, 4, 1881-1903.  
8540744 M.Vaillancourt, G.Sauvé, and E.Cohen (1995).
Antiviral properties of simple difunctionalized enols targeted to the HIV-1 protease.
  Antiviral Res, 27, 205-218.  
  7670378 V.Nauchitel, M.C.Villaverde, and F.Sussman (1995).
Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease.
  Protein Sci, 4, 1356-1364.  
7876898 P.L.Chau, and P.M.Dean (1994).
Electrostatic complementarity between proteins and ligands. 1. Charge disposition, dielectric and interface effects.
  J Comput Aided Mol Des, 8, 513-525.  
7876899 P.L.Chau, and P.M.Dean (1994).
Electrostatic complementarity between proteins and ligands. 2. Ligand moieties.
  J Comput Aided Mol Des, 8, 527-544.  
7964924 R.L.DesJarlais, and J.S.Dixon (1994).
A shape- and chemistry-based docking method and its use in the design of HIV-1 protease inhibitors.
  J Comput Aided Mol Des, 8, 231-242.  
  8381640 P.L.Black, M.B.Downs, M.G.Lewis, M.A.Ussery, G.B.Dreyer, S.R.Petteway, and D.M.Lambert (1993).
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.
  Antimicrob Agents Chemother, 37, 71-77.  
8259000 S.S.Abdel-Meguid (1993).
Inhibitors of aspartyl proteinases.
  Med Res Rev, 13, 731-778.  
8022862 W.Prusoff, T.S.Lin, A.Pivazyan, A.S.Sun, and E.Birks (1993).
Empirical and rational approaches for development of inhibitors of the human immunodeficiency virus--HIV-1.
  Pharmacol Ther, 60, 315-329.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer